This guideline includes statements and recommendations based on available, high-level evidence about the use of chemotherapy for the treatment of advanced breast cancer. The guideline provides health professionals with information designed to help them make management recommendations for improved patient outcomes. NBOCC* also develops information specifically for consumers about the diagnosis and treatment of advanced (secondary) breast cancer.

A clinical practice guideline developed by National Breast And Ovarian Cancer Centre (NBOCC)*

This document supplements guideline recommendation 25 on the use of chemotherapy for the management of advanced breast cancer contained in the National Breast Cancer Centre (NBCC)* Clinical practice guidelines for the management of advanced breast cancer, 2nd edition, 2001 (pages 9-10).

Incorporates published evidence to December 2009

Endorsed by:

• The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
• Medical Oncology Group of Australia Inc. (MOGA)
• The Royal Australasian College of Surgeons

ISBN Print: 978-1-74127-136-2
ISBN Online: 978-1-74127-137-9
CIP: 616.99449061
© Cancer Australia 2011

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.